Financials

  • Market Capitalization 8.04 B
  • Employee 691
  • Founded 2014
  • CEO Rich Adcock
  • Website www.immunitybio.com
  • Headquarter Delaware, United States
  • FIGI BBG007T9DYW9
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-9.02
Relación precio/flujo de caja
51.72

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
1023
TGTX
TG Therapeutics, Inc. - Common Stock
55.85 USD+1.75%-1.33%+11.39%+45.86%8.55 B USD
1033
PCVX
Vaxcyte, Inc. - Common Stock
56.38 USD+0.30%-2.66%+13.74%+33.29%8.14 B USD
1042
IMVT
Immunovant, Inc. - Common Stock
39.44 USD+1.73%-1.42%+18.76%+105.31%8.10 B USD
1061
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
61.94 USD-0.06%-3.92%+18.66%+56.24%7.74 B USD

Noticias